Loading…
Loading…
Establishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth. Preservé delivers over 2x revenue per procedure versus traditional augmentation, but long-term success hinges on repeat utilization and durable economics.
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company.
Deutsche Bank AG purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 128,138 shares of the company's stock, valued at approximately $10,996,000. Deutsche Bank AG owned 0.44%
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript
Establishment Labs NASDAQ: ESTA reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage.
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.57 per share a year ago.
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2026. Second Quarter Highlights and Outlook (Unaudited) Revenue of $67.5 million, up 31.7% from Q2 2025, and sequential growth of 12.8% from Q1 2026 $24.7 million of sales in the United States, up 26% from Q1 2.